The main aim of the European Organization for Research and Treatment of Cancer (EORTC) is to conduct, develop, coordinate and stimulate research in Europe on the experimental and clinical bases of cancer treatment with the final goal being to develop optimal therapeutic strategies in order to improve the standards of cancer treatment in Europe. More than 2000 clinicians/researchers and 283 core medical institutions participate on a voluntary basis in the phase II and large, prospective, randomized, multicenter, phase III clinical trials carried out by 20 different Cooperative Groups. They receive the full logistic and scientific support of the EORTC Data Center, a unique center facility in Europe provides a comprehensive approach to the management of cancer clinical trials. The objectives of the EORTC Data Center are to provide state of the art support to the EORTC Cooperative Groups with respect to data management, computer, statistical and medical expertise at a central and hence economical site. Its goal is to provide and to ensure, from an independent, objective, academic point of view, the highest possible quality of the trial, from its design to the final analysis and publication of the final results. While the EORTC Data Center is concerned with all aspects of trial design, conduct and analysis, Data Center support has recently been given to new areas such as quality assurance, meta-analysis, quality of life, cost effectiveness, and telematics and to new groups dealing with chronotherapy, pathology, and pain and symptom control. New initiatives also involve the development of joint studies with North American Groups and the participation in the elaboration of both Good Clinical Practice guidelines and guidelines from the European Medicine Evaluation Agency on the testing of new anti- cancer drugs. Training and education, quality control and dissemination of information resulting from clinical research are of growing importance from the standpoint of encouraging state of the art treatment for an increasing proportion of cancer patients.
The aim of this competing continuation grant application is to request continuation of the support that the EORTC Data Center has received without interruption since 1974 so that it can pursue, reinforce and expand the range of services which it offers to the well established network of investigators participating in the activities of the EORTC Cooperative Groups.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA011488-28
Application #
2441085
Study Section
Subcommittee G - Education (NCI)
Program Officer
Kaplan, Richard S
Project Start
1981-12-01
Project End
2000-11-30
Budget Start
1998-01-06
Budget End
1998-11-30
Support Year
28
Fiscal Year
1998
Total Cost
Indirect Cost
Name
European Org/Research/Treatment/Cancer
Department
Type
DUNS #
City
Brussels
State
Country
Belgium
Zip Code
1200
Tajik, Parvin; van de Vrie, Roelien; Zafarmand, Mohammad H et al. (2018) The FIGO Stage IVA Versus IVB of Ovarian Cancer: Prognostic Value and Predictive Value for Neoadjuvant Chemotherapy. Int J Gynecol Cancer 28:453-458
Ediebah, Divine E; Reijneveld, Jaap C; Taphoorn, Martin J B et al. (2017) Impact of neurocognitive deficits on patient-proxy agreement regarding health-related quality of life in low-grade glioma patients. Qual Life Res 26:869-880
Seymour, Lesley; Bogaerts, Jan; Perrone, Andrea et al. (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18:e143-e152
Schwartz, Lawrence H; Litière, Saskia; de Vries, Elisabeth et al. (2016) RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer 62:132-7
Baumert, Brigitta G; Hegi, Monika E; van den Bent, Martin J et al. (2016) Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol 17:1521-1532
Schwartz, Lawrence H; Seymour, Lesley; Litière, Saskia et al. (2016) RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. Eur J Cancer 62:138-45
Bonnefoi, H; Jacot, W; Saghatchian, M et al. (2015) Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study. Ann Oncol 26:325-32
Ediebah, Divine E; Galindo-Garre, Francisca; Uitdehaag, Bernard M J et al. (2015) Joint modeling of longitudinal health-related quality of life data and survival. Qual Life Res 24:795-804
Fei, F; Messina, C; Slaets, L et al. (2015) Tumour size is the only predictive factor of distant recurrence after pathological complete response to neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancers: a sub-study of EORTC 10994/BIG 1-00 phase III trial. Eur J Cancer 51:301-9
Oosterveld, Margriet; Suciu, Stefan; Muus, Petra et al. (2015) Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studie Ann Hematol 94:23-34

Showing the most recent 10 out of 338 publications